The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

被引:4
|
作者
Jirapinyo, Pichamol [1 ,2 ,5 ]
Thompson, Christopher C. [1 ,2 ]
Garcia-Tsao, Guadalupe [3 ,4 ]
Zucker, Stephen D. [1 ,2 ]
Ryou, Marvin [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Yale Sch Med, Sect Digest Dis, New Haven, CT USA
[4] VA CT Healthcare Syst, Sect Digest Dis, West Haven, CT USA
[5] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
关键词
LIFE-STYLE; CIRRHOSIS; FIBROSIS; OBESITY;
D O I
10.1055/a-2146-8857
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG. Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasoundguided PPGmeasurement prior to and at 6months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing . 20% reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis. Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/ m2 (range 30.1.56.7) and 14.7 kPa (range 8.2.36), respectively. At 6 months, median PPG decreased from 5.4mmHg (range 0.7.19.6) to 1.8mmHg (range 0.4.17.6) (P = 0.002), with 79% (11/14) experiencing . 20% reduction. Patients experienced 12.5% (6.5%.26.1%) TWL (P < 0.001) at 6 months, with 89% (17/19) achieving . 7% and 68% (13/19) achieving . 10% TWL. There were significant improvements in noninvasive tests of fibrosis. Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. © 2022 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [31] Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease
    Roy, Akash
    De, Arka
    Kulkarni, Anand V.
    Jajodia, Surabhi
    Goenka, Usha
    Tewari, Awanish
    Sonthalia, Nikhil
    Goenka, Mahesh K.
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2024, 33 (03) : 222 - 228
  • [32] IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE?
    Gavril, R. S.
    Mihalache, Laura
    Arhire, Lidia
    Grosu, Cristina
    Gherasim, Andreea
    Nita, Otilia
    Oprescu, A. C.
    Graur, Mariana
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 503 - 507
  • [33] Liver pathology in patients with suspected nonalcoholic fatty liver disease
    Meier, Korrin
    Komorowski, Richard
    Wallace, James
    Nuttleman, Peter
    Andris, Deborah
    Gawrieh, Sumer
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (04) : 708 - 708
  • [34] Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease
    Pimentel, Carolina Frade Magalhaes Girardin
    Lai, Michelle
    MEDICAL CLINICS OF NORTH AMERICA, 2016, 100 (06) : 1303 - +
  • [35] Nonalcoholic fatty liver disease with advanced fibrosis, stroke and cardiovascular disease
    Kawada, Tomoyuki
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 408
  • [36] Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease
    Luo, Kexue
    Bian, Jie
    Wang, Qinxian
    Wang, Jiesheng
    Chen, Fuxing
    Li, Hongchun
    Jan, Dong
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (07): : 611 - 615
  • [37] Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
    Adrian, Therese
    Hornum, Mads
    Knop, Filip Krag
    Almdal, Thomas
    Rossing, Peter
    Lida, Lisa
    Heinrich, Niels Sondergaard
    Boer, Vincent Oltman
    Marsman, Anouk
    Petersen, Esben Thade
    Siebner, Hartwig Roman
    Feldt-Rasmussen, Bo
    NEPHRON, 2023, 147 (06) : 317 - 328
  • [38] Nonalcoholic fatty liver disease
    Alfie, ME
    Treem, WR
    PEDIATRIC ANNALS, 2006, 35 (04): : 290 - +
  • [39] Nonalcoholic fatty liver disease
    Clark, JM
    Brancati, FL
    Diehl, AM
    GASTROENTEROLOGY, 2002, 122 (06) : 1649 - 1657
  • [40] Nonalcoholic fatty liver disease
    Bayard, Max
    Holt, Jim
    Boroughs, Eileen
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (11) : 1961 - 1968